57554-82-2

Upstream product

• 53939-30-3 5-bromo-2-chloropyridine 
• 535-13-7 2-chloro-propanoic acid, ethyl ester 
• 197376-47-9 ethyl (6-chloro-pyridin-3-yl)acetate 
• 74-88-4 methyl iodide 
• 39891-13-9 2-(6-chloropyridin-3-yl)acetic acid 

Downstream Products

• 1419603-63-6 2-(6-benzamidopyridin-3-yl)propanoic acid 
• 1421473-02-0 N-(5-(1-((2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl)methylamino)-1-oxopropan-2-yl)pyridin-2-yl)benzamide 
• 1419603-69-2 ethyl 2-(6-(4-chlorobenzamido)pyridin-3-yl)propanoate 
• 1419603-65-8 ethyl 2-(6-(4-fluorobenzamido)pyridin-3-yl)propanoate 
• 1419599-83-9 N-(5-(1-((3-tert-butyl-1-(3-chlorophenyl)-1H-pyrazol-5-yl)methylamino)-1-oxopropan-2-yl)pyridin-2-yl)-4-chlorobenzamide 
• 1419599-80-6 N-(5-(1-((1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)methylamino)-1-oxopropan-2-yl)pyridin-2-yl)-4-fluorobenzamide 
• 1419603-67-0 2-(6-(4-fluorobenzamido)pyridin-3-yl)propanoic acid 
• 1419599-77-1 N-(5-(1-((3-tert-butyl-1-(3-chlorophenyl)-1H-pyrazol-5-yl)methylamino)-1-oxopropan-2-yl)pyridin-2-yl)-4-fluorobenzamide 
• 1419598-56-3 5-(1-((1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)methylamino)-1-oxopropan-2-yl)picolinamide 
• 1419602-77-9 tert-butyl (5-(1-((1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)methylamino)-1-oxopropan-2-yl)pyridin-2-yl)methylcarbamate 
• 1419603-61-4 ethyl 2-(6-benzamidopyridin-3-yl)propanoate 
• 1421472-28-7 5-(1-((2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl)methylamino)-1-oxopropan-2-yl)-N-phenylpicolinamide 
• 1419599-86-2 4-chloro-N-(5-(1-((1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)methylamino)-1-oxopropan-2-yl)pyridin-2-yl)benzamide 
• 1419603-71-6 2-(6-(4-chlorobenzamido)pyridin-3-yl)propanoic acid 

Relevant academic research and scientific papers

A Metallaphotoredox Strategy for the Cross-Electrophile Coupling of α-Chloro Carbonyls with Aryl Halides

Here, we demonstrate that a metallaphotoredox-catalyzed cross-electrophile coupling mechanism provides a unified method for the α-arylation of diverse activated alkyl chlorides, including α-chloroketones, α-chloroesters, α-chloroamides, α-chlorocarboxylic acids, and benzylic chlorides. This strategy, which is effective for a wide variety of aryl bromide coupling partners, is predicated upon a halogen atom abstraction/nickel radical-capture mechanism that is generically successful across an extensive range of carbonyl substrates. The construction and use of arylacetic acid products have further enabled two-step protocols for the delivery of valuable building blocks for medicinal chemistry, such as aryldifluoromethyl and diarylmethane motifs.

INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE

Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

SUBSTITUTED HETEROCYCLIC AZA DERIVATIVES

The invention relates to heterocyclic aza derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

SUBSTITUTED HETEROAROMATIC PYRAZOLE-CONTAINING CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Substituted Heterocyclic Aza Compounds

Heterocyclic aza compounds as vanilloid receptor ligands, pharmaceutical compositions containing these compounds and also methods of using these compounds for the treatment and/or inhibition of pain and further diseases and/or disorders.

Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands

Substituted heteroaromatic pyrazole-containing carboxamide and urea compounds as vanilloid receptor ligands, pharmaceutical compositions containing these compounds and also to a method of using these compounds for treating and/or inhibiting pain and further diseases and/or disorders.